Key result
Dapagliflozin added to GDMT aids acute myocarditis recovery and cuts NT-proBNP ~62% at 1 month.
Why the study?
Myocarditis is a polymorphic disease with extensive variability in clinical presentation, and its etiology often remains undetermined without an endomyocardial biopsy.
Does adding dapagliflozin to standard guideline-directed medical therapy (beta-blocker and ACE inhibitor) support clinical and biomarker recovery in a young adult with acute myocarditis?
Case Report (n=1)
Open-label
No
Does adding dapagliflozin to standard guideline-directed medical therapy (beta-blocker and ACE inhibitor) support clinical and biomarker recovery in a young adult with acute myocarditis?
Answers are grounded in this paper and cite their sources.
This case report suggests that adding the SGLT2 inhibitor dapagliflozin to standard beta-blocker and ACE inhibitor therapy may support early clinical and biochemical recovery in acute myocarditis.
Background: Myocarditis is a challenging polymorphic disease with extensive variability in clinical presentation. The etiology of myocarditis often remains undetermined without an endomyocardial biopsy. Case presentation: A 25-year-old male with no prior cardiovascular history presented with acute severe retrosternal chest pain, dyspnea, fatigability, and diaphoresis, preceded by mild respiratory symptoms. Physical exam revealed stability, and ECG showed inferolateral ST-segment elevation. Laboratory tests indicated significant myocardial injury with elevated troponin and CK levels, alongside inflammatory markers. Coronary angiography excluded acute coronary syndrome, and cardiac MRI confirmed active myocarditis with characteristic late gadolinium enhancement and myocardial edema. The patient remained hemodynamically stable during hospitalization. Guideline-directed medical therapy was initiated, including a beta-blocker, an ACE inhibitor, and dapagliflozin as an SGLT2 inhibitor to support ventricular recovery and prevent remodeling. At one-month follow-up, the patient was asymptomatic with normalized biomarkers and unremarkable imaging, indicating clinical recovery. Conclusion: This case illustrates that acute myocarditis may lead to early cardiac dysfunction even in young individuals and highlights the potential benefit of adding an SGLT2 inhibitor to standard therapy to support recovery.
No takes yet. Share an insight, caveat, or question.
Suhov et al. (2026) conducted a case report in Acute myocarditis (n=1). Dapagliflozin plus guideline-directed medical therapy (Metoprolol and Ramipril) was evaluated on Clinical recovery and NT-proBNP levels at 1-month follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: